Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)

Phase 1

Active, not recruiting

Conditions: Metastatic Adult Soft Tissue Sarcoma
Drug Toxicity
Maximum Tolerated Dose
GIST
Drug Use

Interventions: Drug: Selinexor
Drug: Imatinib

First Posted Date: 2019-10-24

Last Posted Date: 2023-03-27

Lead Sponsor: Grupo Espanol de Investigacion en Sarcomas

Target Recruit Count: 30

Registration Number: NCT04138381

Locations: 🇪🇸
Hospital Virgen del Rocio, Sevilla, Andalucia, Spain
🇪🇸
H Vall d'Hebrón, Barcelona, Catalonia, Spain
🇪🇸
Hospital Virgen de la Arrixaca, Murcia, Spain

and more 3 locations

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Phase 2

Active, not recruiting

Conditions: BCR-ABL Positive Chronic Myelogenous Leukemia
Philadelphia Chromosome Positive CML

Interventions: Drug: Ponatinib
Drug: Imatinib

First Posted Date: 2019-08-28

Last Posted Date: 2024-04-08

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 170

Registration Number: NCT04070443

Locations: 🇫🇷
CHU Limoges - Hôpital Dupuytren, Limoges, France
🇫🇷
Centre Hospitalier Annecy-Genevois, Annecy, France
🇫🇷
Iuct Toulouse - Oncopole, Toulouse, France

and more 25 locations

Frontline Asciminib Combination in Chronic Phase CML

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Asciminib
Drug: Dasatinib
Drug: Nilotinib 300 mg
Drug: Imatinib

First Posted Date: 2019-04-08

Last Posted Date: 2023-05-10

Lead Sponsor: University of Jena

Target Recruit Count: 125

Registration Number: NCT03906292

Locations: 🇩🇪
Universitätsklinikum Aachen Medizinische Klinik IV, Aachen, Germany
🇩🇪
Klinikum Bremen Mitte, Bremen, Germany
🇩🇪
Charite Universitätsmeditin Berlin, Campus Virchow Klinikum, Berlin, Germany

and more 18 locations

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Imatinib
Drug: Isoniazid
Drug: Rifabutin

First Posted Date: 2019-03-27

Last Posted Date: 2023-10-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT03891901

Locations: 🇺🇸
Emory University DAIDS TB Non-Network CRS, Atlanta, Georgia, United States

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Completed

Conditions: CML - Philadelphia Chromosome
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, Chronic Phase
CML, Chronic Phase
CML (Chronic Myelogenous Leukemia

Interventions: Drug: Bosutinib
Drug: Dasatinib
Drug: Imatinib
Drug: Nilotinib

First Posted Date: 2019-03-22

Last Posted Date: 2023-01-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT03885830

Locations: 🇺🇸
UNC Hospital, Chapel Hill, North Carolina, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Phase 4

Conditions: Hematological Neoplasms

Interventions: Drug: Bortezomib
Drug: Eltrombopag
Drug: Imatinib
Drug: dasatinib
Drug: Pegaspargase
Drug: Anti-Infective Drugs
Drug: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

First Posted Date: 2019-02-18

Last Posted Date: 2020-01-10

Lead Sponsor: Wei Zhao

Target Recruit Count: 1500

Registration Number: NCT03844360

Locations: 🇨🇳
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Phase 3

Active, not recruiting

Conditions: Chronic Myeloid Leukemia, Chronic Phase

Interventions: Drug: Radotinib
Drug: Imatinib

First Posted Date: 2018-10-29

Last Posted Date: 2024-10-28

Lead Sponsor: Il-Yang Pharm. Co., Ltd.

Target Recruit Count: 238

Registration Number: NCT03722420

Locations: 🇨🇳
Peking University People's Hospital(北京大学人民医院), Beijing, China

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

Phase 2

Conditions: Plasmodium Falciparum Malaria (Drug Resistant)

Interventions: Drug: Imatinib
Drug: Dihydroartemisinin-piperaquine

First Posted Date: 2018-10-05

Last Posted Date: 2018-10-05

Lead Sponsor: Nurex S.r.l.

Target Recruit Count: 50

Registration Number: NCT03697668

Locations: 🇻🇳
A Tuc, Hương Hóa, Quang Tri, Vietnam

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Bosutinib
Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Drug: Nilotinib
Drug: Ruxolitinib
Drug: Imatinib

First Posted Date: 2018-08-31

Last Posted Date: 2024-07-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 84

Registration Number: NCT03654768

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 537 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy